Generate Biomedicines
GENB
9.54
-0.83
-8.00%
Generate Biomedicines
US · GENB
#2875 by market cap
Listed 2026
9.54
-0.83
-8.00%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:32
Recent news
-
Rating change
H.C. Wainwright Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $16Market Newswire · 2026/4/13
-
Rating change
Guggenheim Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/6/25
-
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/11/13
-
Rating change
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $25Market Newswire · 2026/5/8
-
Rating change
Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK Hynix Inc. Sponsored GDR (OtherHXSCL)TipRanks · 2026/6/25
-
Earnings Flash (GENB) Generate Biomedicines Posts Q3 Net Loss $0.68 a Share, Vs. FactSet Est of $0.56 LossMT Newswires · 2026/11/12
-
Rating change
Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)TipRanks · 2026/6/15
-
Rating change
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30Market Newswire · 2026/8/28
-
Rating change
Analysts Offer Insights on NA Companies: Guidewire (GWRE) and Generate Biomedicines, Inc. (GENB)TipRanks · 2026/9/9
-
Rating change
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24Market Newswire · 2026/8/7
-
Rating change
Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)TipRanks · 2026/8/17
-
Rating change
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22Market Newswire · 2026/8/17
-
Rating change
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $25Market Newswire · 2026/8/7
-
Rating change
Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)TipRanks · 2026/5/8
-
Earnings Flash (GENB) Generate Biomedicines, Inc. Reports Q3 Collaboration Revenue $4.2MMT Newswires · 2026/11/12
-
Rating change
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $26Market Newswire · 2026/10/14
-
Rating change
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22Market Newswire · 2026/5/14
-
Piper Sandler Keeps Their Buy Rating on Generate Biomedicines, Inc. (GENB)TipRanks · 2026/10/14
-
Analysts Are Bullish on Top NA Stocks: Generate Biomedicines, Inc. (GENB), Netskope, Inc. (NTSK)TipRanks · 2026/10/2
-
Rating change
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $26Market Newswire · 2026/10/2
-
Rating change
Goldman Sachs Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $26Market Newswire · 2026/4/11
-
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/10/30
-
Rating change
Goldman Sachs Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $26Market Newswire · 2026/3/25
-
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/10/15
-
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/10/5
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:32:29 · For reference only, not investment advice and not tailored to your situation.
Generate Biomedicines discussion 0 comments